{
    "root": "31420e86-ee3b-e6b1-e063-6394a90aefc7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Timolol Maleate",
    "value": "20250326",
    "ingredients": [
        {
            "name": "GELLAN GUM (LOW ACYL)",
            "code": "7593U09I4D"
        },
        {
            "name": "TROMETHAMINE",
            "code": "023C2WHX2V"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "BENZODODECINIUM BROMIDE",
            "code": "IRY12B2TQ6"
        },
        {
            "name": "TIMOLOL MALEATE",
            "code": "P8Y54F701R"
        }
    ],
    "indications": "timolol maleate sterile ophthalmic gel forming solution indicated treatment elevated intraocular pressure patients ocular hypertension open-angle glaucoma .",
    "contraindications": "patients instructed invert closed container shake . necessary shake container . topically applied ophthalmic medications administered least 10 minutes timolol maleate ophthalmic gel forming solution [ , information patients accompanying instructions ] . timolol maleate sterile ophthalmic gel forming solution available concentrations 0.25 % 0.5 % . dose one drop timolol maleate ophthalmic gel forming solution ( either 0.25 % 0.5 % ) affected eye ( ) day . patients pressure-lowering response timolol maleate ophthalmic gel forming solution may require weeks stabilize , evaluation include determination intraocular pressure approximately 4 weeks treatment timolol maleate ophthalmic gel forming solution . dosages higher one drop 0.5 % timolol maleate ophthalmic gel forming solution day studied . patient \u2019 intraocular pressure still satisfactory level regimen , concomitant therapy considered . concomitant two topical beta-adrenergic blocking agents recommended [ , , beta-adrenergic blocking agents ] . patients switched therapy timolol maleate ophthalmic solution administered twice daily timolol maleate ophthalmic gel forming solution administered daily , ocular hypotensive effect remained consistent .",
    "warningsAndPrecautions": "timolol maleate ophthalmic gel forming solution colorless nearly colorless , slightly opalescent , slightly viscous solution . timolol maleate ophthalmic gel forming solution , 0.25 % timolol equivalent , supplied white low density polyethylene ( ldpe ) dispenser controlled drop tip yellow polypropylene cap follows : ndc 82260-818-25 , 5 ml 7.5 ml capacity bottle . timolol maleate ophthalmic gel forming solution , 0.5 % timolol equivalent , supplied white low density polyethylene ( ldpe ) dispenser controlled drop tip yellow polypropylene cap follows : ndc 82260-819-05 , 5 ml 7.5 ml capacity bottle . storage store 15\u00b0c 25\u00b0c ( 59\u00b0f 77\u00b0f ) . avoid freezing.protect light . distributed : bausch & lomb americas inc. bridgewater , nj 08807 usa manufactured : bausch & lomb incorporated tampa , fl 33637 usa \u00a9 2022 bausch & lomb incorporated affiliates revised : 03/2022 9753401",
    "adverseReactions": "timolol maleate ophthalmic gel forming solution contraindicated patients ( 1 ) bronchial asthma ; ( 2 ) history bronchial asthma ; ( 3 ) severe chronic obstructive pulmonary disease [ , obstructive pulmonary disease ] ; ( 4 ) sinus bradycardia ; ( 5 ) second third degree atrioventricular block ; ( 6 ) overt cardiac failure [ , cardiac failure ] ; ( 7 ) cardiogenic shock ; ( 8 ) hypersensitivity component product .",
    "indications_original": "Timolol Maleate Sterile Ophthalmic Gel Forming Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.",
    "contraindications_original": "Patients should be instructed to invert the closed container and shake once before each use. It is not necessary to shake the container more than once. Other topically applied ophthalmic medications should be administered at least 10 minutes before Timolol Maleate Ophthalmic Gel Forming Solution [see\n \n  \n                        PRECAUTIONS,\n  \n   Information for Patients\n                     and accompanying\n \n  \n                        INSTRUCTIONS FOR USE\n                     ].\n\n \n                  Timolol Maleate Sterile Ophthalmic Gel Forming Solution is available in concentrations of 0.25% and 0.5%. The dose is one drop of Timolol Maleate Ophthalmic Gel Forming Solution (either 0.25% or 0.5%) in the affected eye(s) once a day.\n                  Because in some patients the pressure-lowering response to Timolol Maleate Ophthalmic Gel Forming Solution may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with Timolol Maleate Ophthalmic Gel Forming Solution.\n                  Dosages higher than one drop of 0.5% Timolol Maleate Ophthalmic Gel Forming Solution once a day have not been studied. If the patient\u2019s intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy can be considered. The concomitant use of two topical beta-adrenergic blocking agents is not recommended [see\n \n  \n                        PRECAUTIONS,\n  \n   Drug Interactions,\n  \n   Beta-Adrenergic Blocking Agents\n                     ].\n\n \n                  When patients have been switched from therapy with Timolol Maleate Ophthalmic Solution administered twice daily to Timolol Maleate Ophthalmic Gel Forming Solution administered once daily, the ocular hypotensive effect has remained consistent.",
    "warningsAndPrecautions_original": "Timolol Maleate Ophthalmic Gel Forming Solution is a colorless to nearly colorless, slightly opalescent, and slightly viscous solution.\n                  Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% timolol equivalent, is supplied in a white low density polyethylene (LDPE) dispenser with a controlled drop tip and a yellow polypropylene cap as follows:\n                  \n                     NDC 82260-818-25, 5 mL in a 7.5 mL capacity bottle.\n\n \n                  Timolol Maleate Ophthalmic Gel Forming Solution, 0.5% timolol equivalent, is supplied in a white low density polyethylene (LDPE) dispenser with a controlled drop tip and a yellow polypropylene cap as follows:\n                  \n                     NDC 82260-819-05, 5 mL in a 7.5 mL capacity bottle.\n\n \n                  \n                     Storage\n                       Store at 15\u00b0C to 25\u00b0C (59\u00b0F to 77\u00b0F).\n \n  Avoid freezing.Protect from light.\n\n \n                  \n                     Distributed by:\n                       Bausch & Lomb Americas Inc. \n    Bridgewater, NJ 08807 USA \n  \n                     \n                     Manufactured by:\n                       Bausch & Lomb Incorporated \n    Tampa, FL 33637 USA \n    \u00a9 2022 Bausch & Lomb Incorporated or its affiliates \n    Revised: 03/2022\n\n \n                  9753401",
    "adverseReactions_original": "Timolol Maleate Ophthalmic Gel Forming Solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see\n \n  \n                        WARNINGS,\n  \n   Obstructive Pulmonary Disease\n                     ]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see\n \n  \n                        WARNINGS,\n  \n   Cardiac Failure\n                     ]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product."
}